VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

NACLC 2022 | Personalized therapies for patients with KRAS-mutant lung cancer

Biagio Ricciuti, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of personalized therapies for patients with lung cancer harboring KRAS G12C, G12D and G12V mutations. Whilst immunotherapy has predominantly been used to treat KRAS G12C-mutatnt lung cancer, the arrival of sotorasib and adagrasib has improved outcomes in patients. KRAS G12D, which typically is found in never-smokers, has been an unmet need and MRTX1133 has shown encouraging efficacy in preliminary studies. Dr Ricciuti additionally highlights RMC-6236, a novel oral RAS(ON) inhibitor, which will hopefully successfully target KRAS mutations in different cancers. This interview took place at the IASLC 2022 North America Conference on Lung Cancer (NACLC 2022).

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Biagio Ricciuti, MD, is a consultant/advisory board for Regeneron.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter